Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

NCT05993234

Active Not RecruitingN/A

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Conditions: HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma

Interventions: Trastuzumab deruxtecan

Countries: Austria, Belgium, Germany, Italy

Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. This study will assess the effectiveness of T-DXd, patient demographic and clinical characteristics, and treatment patterns in patients with advanced HER2-positive advanced gastric or GEJ adenocarcinoma.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Male or female adult patient (age ≥ 18 years) with HER2 + advanced gastric or GEJ adenocarcinoma who have received a prior trastuzumab based regimen
* Histological or cytological confirmed diagnosis of advanced HER2 positive gastric cancer or GEJ
* Documented HER2 + status (archival sample or recent sample prior 2L therapy)
* Decision to newly initiate monotherapy T-DXd or conventional therapies per SMPC according to the physician's choice
* Written dated and signed Informed Consent (ICF) to participate in the study

Exclusion Criteria:

* Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded
* Pregnancy or breastfeeding

No specific exclusion criteria are defined, as patients will be treated according to the proposed indication statements in the SmPC.
Locations (39)
  • Linz, Austria
  • Vienna, Austria
  • Wels, Austria
  • Wiener Neustadt, Austria
  • Zams, Austria
  • Aalst, Belgium
  • Edegem, Belgium
  • Ghent, Belgium
  • Haine-Saint-Paul, Belgium
  • Hasselt, Belgium
  • Jette, Belgium
  • Aschaffenburg, Germany
  • Berlin, Germany
  • Berlin, Germany
  • Cologne, Germany
  • Essen, Germany
  • Göppingen, Germany
  • Hamburg, Germany
  • Hanover, Germany
  • Hanover, Germany
  • Hanover, Germany
  • München, Germany
  • Reutlingen, Germany
  • Saarbrücken, Germany
  • Troisdorf, Germany
  • Castellana Grotte, Italy
  • Catania, Italy
  • Florence, Italy
  • Genova, Italy
  • Milan, Italy
  • + 9 more on CT.gov